Viatris Inc (VTRS)

$16.99 -0.30 (-1.74%)
Market Cap 20.14B
Revenue (ttm) 14.30B
Net Income (ttm) -3.51B
EPS (ttm) N/A
PE Ratio 7.07
Forward PE 7.03
Profit Margin -24.58%
Debt to Equity Ratio 0.98
Volume 7,852,900
Avg Vol 10,748,532
Day's Range N/A - N/A
Shares Out 1.16B
Stochastic %K 60%
Beta 0.91
Analysts Sell
Price Target $18.11

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
HarveyToronto
HarveyToronto Jul. 20 at 10:10 PM
$VTRS got assigned at 17 due to my covered calls. Will buyback under 16.
0 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 11:30 AM
$PMN with the Platform 💊 of PMN310 for Alzheimer Disease ProMIS is also targeting: 5. Frontotemporal Dementia (FTD) Pharmaceutical sales 2026: approx. USD 120 to 250 million (market for specific, targeted drugs). Leading companies (market leaders): There is no disease-modifying therapy specifically approved for FTD; the market is served entirely through off-label use. Revenues are distributed among major generics manufacturers (such as Teva, $VTRS , or $SDZXF ) for the use of selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics to manage behavioral symptoms. Promising pipeline candidate: $ALEC (in collaboration with $GLAXO.NSE ) is developing latazanemab (AL001)—this represents the future growth potential for the FTD niche market.
0 · Reply
dllydalley29
dllydalley29 Jul. 17 at 1:48 PM
$VTRS We still have a long way to go to get even close to the valuation of Teva. Hopefully as this rallies, the disconnect will narrow. Good luck longs.
0 · Reply
SniperPro
SniperPro Jul. 15 at 6:26 PM
$LXRX $VTRS $NVO Breaking News: Lexicon accidentally discovers the Fountain of Youth... 🧬⛲ *SATIRE* Wall Street doesn't wait for the data... Analysts immediately slap on $500 price targets, CNBC calls it a "generational opportunity," and every fund manager suddenly claims they "saw it coming all along." 📈🚀💰 The company tries to explain it's still early research... Too late. Someone rebrands it to "Ever," adds "AI-powered longevity platform" to the investor deck, and the market rewards it with a $100 billion valuation fueled by nothing but narrative, multiple expansion, and pure LUCK!!! 😂🤖✨ *Lexicon Pharmaceuticals utilizes its proprietary target discovery platform, Genome5000™, to systematically uncover the functions of nearly 5,000 genes. By applying Nobel Prize-winning gene-knockout technology, Lexicon has identified over 100 protein targets to pioneer precision medicines for neuropathic pain, heart failure, obesity, and other diseases. Live Forever... ?
1 · Reply
Bazziggr
Bazziggr Jul. 14 at 11:00 PM
$VTRS AGX
0 · Reply
ItsCarRamRod
ItsCarRamRod Jul. 9 at 8:02 PM
$VTRS escalator up & elevator down.
0 · Reply
Kocatka
Kocatka Jul. 9 at 8:00 PM
$LXRX $NVO $VTRS $NVO 💯
0 · Reply
SniperPro
SniperPro Jul. 9 at 7:45 PM
$LXRX $NVO $VTRS You want VOLUME? Fine—you got it... 🔊😏 I'll give Lex some credit where it's due, but I'm absolutely fed up with the clown management for failing to keep shareholders updated... 🤦‍♂️🎪 I've spent years emailing them, asking for basic communication, and I'm honestly tired of wasting my time... 😤📧 Perhaps my heart and soul finally accepted the obvious: I'm dealing with people who simply don't get it, and you can't fix stupid... 🤷‍♂️🙄 Yes, Ray and Exton—I'm talking about you two clowns... 🤡🤡 Shareholders deserved updates years ago, not endless silence and excuses... ⏳😑 It wouldn't shock me if $NVO finally decided to step in with a hostile takeover and put an end to this circus... 🤡🎪 At this point, a change in leadership might be the only way to bring some accountability and finally get shareholders the communication they deserve... 📢🙄 Apparently, keeping investors informed is just too much to ask... 😂📢
1 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Jul. 8 at 4:58 PM
$MNKD $REPL $CAPR $VTRS Absolute stacked PDUFA line up coming up This is the summer of biotech binaries for sure Time to make a fortune :)
4 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 29 at 5:03 PM
$LXRX Medicare coverage approval for GLP1's sets a precedent for LX9851 to be approved under the Medicare Umbrella, as well. If Congress approves to re-instate the program after 2027. Second, Sotagliflozin for Type1 DOES HAVE WEIGHT LOSS EFFECTS-They are NOT minor-like 20-30% if I recall correctly. And could be added as an extra benefit, and PERHAPS under the Medicare GLP1 coverage could act as a weight loss indication approval for** T1 Diabetics** - which would only ADD to their benefit as per their diabetic condition. https://www.medicare.gov/coverage/weight-loss-drugs $VTRS $NVO + $LXRX
0 · Reply
Latest News on VTRS
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows

Jul 13, 2026, 9:19 AM EDT - 7 days ago

Mylan to sell up to $363 million stake in India's Biocon, term sheet shows

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

Jul 1, 2026, 6:59 AM EDT - 19 days ago

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

Viatris announces VR-205 trial achieves primary endpoint

2026-06-29T11:05:13.000Z - 21 days ago

Viatris announces VR-205 trial achieves primary endpoint

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Jun 29, 2026, 6:59 AM EDT - 21 days ago

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Viatris price target raised to $22 from $17 at Barclays

2026-05-19T09:20:10.000Z - 2 months ago

Viatris price target raised to $22 from $17 at Barclays

Viatris says FDA accepts for review NDA for MR-107A-02

2026-05-18T12:09:01.000Z - 2 months ago

Viatris says FDA accepts for review NDA for MR-107A-02

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

May 18, 2026, 8:00 AM EDT - 2 months ago

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Viatris Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 11:00 AM EDT - 2 months ago

Viatris Transcript: Bank of America Global Healthcare Conference 2026

Viatris price target raised to $20 from $18 at Truist

2026-05-08T14:11:09.000Z - 2 months ago

Viatris price target raised to $20 from $18 at Truist

Viatris price target raised to $18 from $17 at JPMorgan

2026-05-08T12:28:39.000Z - 2 months ago

Viatris price target raised to $18 from $17 at JPMorgan

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

May 7, 2026, 4:30 PM EDT - 2 months ago

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

Viatris beats quarterly estimates on China strength, branded drug sales

May 7, 2026, 12:30 PM EDT - 2 months ago

Viatris beats quarterly estimates on China strength, branded drug sales

Viatris reports Q1 adjusted EPS 59c, consensus 50c

2026-05-07T16:28:39.000Z - 2 months ago

Viatris reports Q1 adjusted EPS 59c, consensus 50c

Viatris backs FY26 adjusted EPS view $2.23-$2.47, consensus $2.44

2026-05-07T16:25:38.000Z - 2 months ago

Viatris backs FY26 adjusted EPS view $2.23-$2.47, consensus $2.44

Viatris Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Viatris Earnings Call Transcript: Q1 2026

Viatris Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Viatris Slides: Q1 2026

Viatris Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Viatris Earnings release: Q1 2026

Viatris Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Viatris Quarterly report: Q1 2026

Viatris Reports First-Quarter 2026 Financial Results

May 7, 2026, 6:59 AM EDT - 2 months ago

Viatris Reports First-Quarter 2026 Financial Results

Viatris Announces Quarterly Dividend

May 5, 2026, 6:59 AM EDT - 2 months ago

Viatris Announces Quarterly Dividend

Viatris CFO Theodora Mistras to depart, Paul Campbell named interim CFO

2026-05-04T20:46:39.000Z - 2 months ago

Viatris CFO Theodora Mistras to depart, Paul Campbell named interim CFO

Viatris Announces Chief Financial Officer Transition

May 4, 2026, 4:30 PM EDT - 2 months ago

Viatris Announces Chief Financial Officer Transition

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

May 1, 2026, 6:59 AM EDT - 2 months ago

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 13, 2026, 6:59 AM EDT - 3 months ago

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 10, 2026, 6:59 AM EDT - 3 months ago

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Viatris Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Viatris Proxy statement: Proxy filing

Viatris Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Viatris Proxy statement: Proxy filing

Viatris price target raised to $17 from $15 at Barclays

2026-03-24T09:41:03.000Z - 4 months ago

Viatris price target raised to $17 from $15 at Barclays

Viatris announces approval for Effexor SR 37.5 mg / 75 mg capsules in Japan

2026-03-23T11:20:10.000Z - 4 months ago

Viatris announces approval for Effexor SR 37.5 mg / 75 mg capsules in Japan

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

Mar 23, 2026, 6:59 AM EDT - 4 months ago

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

Viatris Transcript: Investor update

Mar 19, 2026, 10:00 AM EDT - 4 months ago

Viatris Transcript: Investor update

Viatris Press release: Investor update

Mar 19, 2026, 10:00 AM EDT - 4 months ago

Viatris Press release: Investor update

Viatris Slides: Investor update

Mar 19, 2026, 10:00 AM EDT - 4 months ago

Viatris Slides: Investor update

Viatris outlines vision for growth through 2030

2026-03-19T13:15:32.000Z - 4 months ago

Viatris outlines vision for growth through 2030

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

Mar 19, 2026, 8:30 AM EDT - 4 months ago

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research

Mar 12, 2026, 11:11 AM EDT - 4 months ago

Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research

These S&P 500 stocks are falling the hardest on Tuesday

Mar 3, 2026, 10:41 AM EST - 4 months ago

These S&P 500 stocks are falling the hardest on Tuesday

ALB APO ARES BX CIEN FCX GEV

AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.

Feb 27, 2026, 1:03 PM EST - 5 months ago

AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.

DASH DPZ SJM

Viatris price target raised to $20 from $18 at UBS

2026-02-27T13:13:30.000Z - 5 months ago

Viatris price target raised to $20 from $18 at UBS

Viatris forecasts 2026 profit below estimates on India manufacturing woes

Feb 26, 2026, 8:37 AM EST - 5 months ago

Viatris forecasts 2026 profit below estimates on India manufacturing woes

Viatris Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

Viatris Earnings Call Transcript: Q4 2025

Viatris Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

Viatris Annual report: Q4 2025

Viatris Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

Viatris Earnings release: Q4 2025

Viatris Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 5 months ago

Viatris Slides: Q4 2025

Viatris sees FY26 adjusted EPS $2.33-$2.47, consensus $2.49

2026-02-26T12:14:26.000Z - 5 months ago

Viatris sees FY26 adjusted EPS $2.33-$2.47, consensus $2.49

Viatris reports Q4 adjusted EPS 57c, consensus 53c

2026-02-26T12:07:02.000Z - 5 months ago

Viatris reports Q4 adjusted EPS 57c, consensus 53c

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

Feb 26, 2026, 6:59 AM EST - 5 months ago

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

Feb 26, 2026, 6:55 AM EST - 5 months ago

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

Viatris announces FDA acceptance of review for MR-141 sNDA

2026-02-25T12:05:34.000Z - 5 months ago

Viatris announces FDA acceptance of review for MR-141 sNDA

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

Feb 25, 2026, 6:59 AM EST - 5 months ago

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

Feb 19, 2026, 9:02 AM EST - 5 months ago

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

Feb 3, 2026, 4:34 PM EST - 5 months ago

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Feb 3, 2026, 8:30 AM EST - 5 months ago

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Jan 20, 2026, 6:59 AM EST - 6 months ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

LXRX

Viatris Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:00 PM EST - 6 months ago

Viatris Transcript: 44th Annual J.P. Morgan Healthcare Conference

Viatris Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:00 PM EST - 6 months ago

Viatris Slides: 44th Annual J.P. Morgan Healthcare Conference

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Jan 8, 2026, 9:05 AM EST - 6 months ago

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Jan 6, 2026, 9:00 AM EST - 6 months ago

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Viatris Provides Pipeline Update on Four Regulatory Milestones

Dec 18, 2025, 6:59 AM EST - 7 months ago

Viatris Provides Pipeline Update on Four Regulatory Milestones

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 6:59 AM EST - 7 months ago

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Dec 6, 2025, 9:00 AM EST - 8 months ago

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Viatris Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 8:45 AM EST - 8 months ago

Viatris Transcript: Evercore ISI 8th Annual HealthCONx Conference

Viatris Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 8:30 AM EST - 8 months ago

Viatris Transcript: Piper Sandler 37th Annual Healthcare Conference

Viatris to Participate in Upcoming Investor Conferences

Nov 24, 2025, 8:00 AM EST - 8 months ago

Viatris to Participate in Upcoming Investor Conferences

Viatris Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 6:30 AM EST - 8 months ago

Viatris Transcript: Jefferies London Healthcare Conference 2025

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

Nov 13, 2025, 8:00 AM EST - 8 months ago

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

Viatris Transcript: UBS Global Healthcare Conference 2025

Nov 11, 2025, 8:45 AM EST - 8 months ago

Viatris Transcript: UBS Global Healthcare Conference 2025

Viatris Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Viatris Earnings Call Transcript: Q3 2025

Viatris Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Viatris Quarterly report: Q3 2025

Viatris Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Viatris Earnings release: Q3 2025

Viatris Slides: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Viatris Slides: Q3 2025

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Nov 6, 2025, 8:16 AM EST - 9 months ago

Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Nov 6, 2025, 6:59 AM EST - 9 months ago

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Viatris Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 9 months ago

Viatris Proxy statement: Proxy Filing

Viatris Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 9 months ago

Viatris Proxy statement: Proxy Filing

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Oct 15, 2025, 4:30 PM EDT - 9 months ago

Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Oct 8, 2025, 11:00 AM EDT - 10 months ago

Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 1, 2025, 9:00 AM EDT - 10 months ago

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Aug 19, 2025, 9:00 AM EDT - 11 months ago

Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Aug 11, 2025, 9:29 AM EDT - 1 year ago

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Aug 7, 2025, 9:36 AM EDT - 1 year ago

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise

Viatris Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Viatris Earnings Call Transcript: Q2 2025

Viatris Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Viatris Quarterly report: Q2 2025

Viatris Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Viatris Earnings release: Q2 2025

Viatris Slides: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Viatris Slides: Q2 2025

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Aug 7, 2025, 6:59 AM EDT - 1 year ago

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Aug 5, 2025, 6:55 AM EDT - 1 year ago

Viatris Announces Appointment of David Simmons to the Company's Board of Directors

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

Aug 1, 2025, 10:00 AM EDT - 1 year ago

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

Jul 22, 2025, 11:19 AM EDT - 1 year ago

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

CIVI CMCSA CRGY CWEN KSS LNC NXST

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Jul 18, 2025, 8:47 AM EDT - 1 year ago

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 1 year ago

Viatris eye therapy fails to meet late-stage trial goal

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Jul 18, 2025, 6:59 AM EDT - 1 year ago

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Jun 26, 2025, 6:55 AM EDT - 1 year ago

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 12, 2025, 4:30 PM EDT - 1 year ago

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

HarveyToronto
HarveyToronto Jul. 20 at 10:10 PM
$VTRS got assigned at 17 due to my covered calls. Will buyback under 16.
0 · Reply
GoforProMIS
GoforProMIS Jul. 20 at 11:30 AM
$PMN with the Platform 💊 of PMN310 for Alzheimer Disease ProMIS is also targeting: 5. Frontotemporal Dementia (FTD) Pharmaceutical sales 2026: approx. USD 120 to 250 million (market for specific, targeted drugs). Leading companies (market leaders): There is no disease-modifying therapy specifically approved for FTD; the market is served entirely through off-label use. Revenues are distributed among major generics manufacturers (such as Teva, $VTRS , or $SDZXF ) for the use of selective serotonin reuptake inhibitors (SSRIs) and atypical antipsychotics to manage behavioral symptoms. Promising pipeline candidate: $ALEC (in collaboration with $GLAXO.NSE ) is developing latazanemab (AL001)—this represents the future growth potential for the FTD niche market.
0 · Reply
dllydalley29
dllydalley29 Jul. 17 at 1:48 PM
$VTRS We still have a long way to go to get even close to the valuation of Teva. Hopefully as this rallies, the disconnect will narrow. Good luck longs.
0 · Reply
SniperPro
SniperPro Jul. 15 at 6:26 PM
$LXRX $VTRS $NVO Breaking News: Lexicon accidentally discovers the Fountain of Youth... 🧬⛲ *SATIRE* Wall Street doesn't wait for the data... Analysts immediately slap on $500 price targets, CNBC calls it a "generational opportunity," and every fund manager suddenly claims they "saw it coming all along." 📈🚀💰 The company tries to explain it's still early research... Too late. Someone rebrands it to "Ever," adds "AI-powered longevity platform" to the investor deck, and the market rewards it with a $100 billion valuation fueled by nothing but narrative, multiple expansion, and pure LUCK!!! 😂🤖✨ *Lexicon Pharmaceuticals utilizes its proprietary target discovery platform, Genome5000™, to systematically uncover the functions of nearly 5,000 genes. By applying Nobel Prize-winning gene-knockout technology, Lexicon has identified over 100 protein targets to pioneer precision medicines for neuropathic pain, heart failure, obesity, and other diseases. Live Forever... ?
1 · Reply
Bazziggr
Bazziggr Jul. 14 at 11:00 PM
$VTRS AGX
0 · Reply
ItsCarRamRod
ItsCarRamRod Jul. 9 at 8:02 PM
$VTRS escalator up & elevator down.
0 · Reply
Kocatka
Kocatka Jul. 9 at 8:00 PM
$LXRX $NVO $VTRS $NVO 💯
0 · Reply
SniperPro
SniperPro Jul. 9 at 7:45 PM
$LXRX $NVO $VTRS You want VOLUME? Fine—you got it... 🔊😏 I'll give Lex some credit where it's due, but I'm absolutely fed up with the clown management for failing to keep shareholders updated... 🤦‍♂️🎪 I've spent years emailing them, asking for basic communication, and I'm honestly tired of wasting my time... 😤📧 Perhaps my heart and soul finally accepted the obvious: I'm dealing with people who simply don't get it, and you can't fix stupid... 🤷‍♂️🙄 Yes, Ray and Exton—I'm talking about you two clowns... 🤡🤡 Shareholders deserved updates years ago, not endless silence and excuses... ⏳😑 It wouldn't shock me if $NVO finally decided to step in with a hostile takeover and put an end to this circus... 🤡🎪 At this point, a change in leadership might be the only way to bring some accountability and finally get shareholders the communication they deserve... 📢🙄 Apparently, keeping investors informed is just too much to ask... 😂📢
1 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Jul. 8 at 4:58 PM
$MNKD $REPL $CAPR $VTRS Absolute stacked PDUFA line up coming up This is the summer of biotech binaries for sure Time to make a fortune :)
4 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 29 at 5:03 PM
$LXRX Medicare coverage approval for GLP1's sets a precedent for LX9851 to be approved under the Medicare Umbrella, as well. If Congress approves to re-instate the program after 2027. Second, Sotagliflozin for Type1 DOES HAVE WEIGHT LOSS EFFECTS-They are NOT minor-like 20-30% if I recall correctly. And could be added as an extra benefit, and PERHAPS under the Medicare GLP1 coverage could act as a weight loss indication approval for** T1 Diabetics** - which would only ADD to their benefit as per their diabetic condition. https://www.medicare.gov/coverage/weight-loss-drugs $VTRS $NVO + $LXRX
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Jun. 28 at 2:26 PM
$VTRS cup/handle + break above resistance on handle = sauce
0 · Reply
diegomontana
diegomontana Jun. 26 at 4:23 PM
$VTRS 1,70 back then 6,80 now
0 · Reply
SniperPro
SniperPro Jun. 26 at 2:02 PM
$LXRX $NVO $VTRS $SPY 🚂 ALL ABOARD!!!!!!! 🚂 UP WE GO!!! 🚀🐳💰💥 ...
0 · Reply
SniperPro
SniperPro Jun. 25 at 3:02 PM
$LXRX $NVO $VTRS 🚂 ALL ABOARD!!!!!!! 🚂 $SPY It’s happening, so you might as well get on board and keep up with the program... 🚂💨 You can keep resisting if you'd like, but reality seems pretty committed to moving forward... 🤷‍♂️📈 Sometimes you just have to go with the flow.... 🌊😎 LFG!!! 🚀🔥
1 · Reply
dllydalley29
dllydalley29 Jun. 24 at 5:54 PM
$VTRS Let's get back to 16 bucks. Pharma stocks been down too long, especially VTRS.
0 · Reply
SniperPro
SniperPro Jun. 24 at 4:59 PM
$LXRX $NVO $VTRS 😂 The best part is that every investor has that moment: "Why is this person buying so aggressively? Do they know something?" Then six months later you find out they either: Had incredible insight, Had absolutely no idea what they were doing, Or accidentally clicked "Buy" 47 times and became a legend. Until proven otherwise: 🚂 ALL ABOARD!!!!!!! 🚂 📈 Trend: Up 🚀 Destination: North 🤠 Risk Management: What's that? Good luck with the position! 😆
1 · Reply
SniperPro
SniperPro Jun. 24 at 4:54 PM
$LXRX $NVO $VTRS 🚂 ALL ABOARD!!!!!!! 🚂 $SPY We're going up whether they like it or not. Someone keeps competing with me for shares, and judging by the way they're buying, they've either got inside knowledge of the future or cojones made of reinforced steel. Naturally, I'm wondering if they know something my research team missed. But all I know is this train isn't slowing down, and the destination board keeps flashing NORTH. 📈 Maybe they found gold. Maybe they cracked some secret code. Maybe we're all just piling onto the same rocket and asking questions later. Either way, the engines are fired up, the tickets are punched, and this elevator only seems to have one button: UP. 🚀 So grab a seat, keep your hands and feet inside the vehicle at all times, and enjoy the ride. Next stop: Higher. After that? Even higher. ALL ABOARD!!!!!!! 🚂📈🚀
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 23 at 3:07 PM
$LXRX $NVO $LLY $VTRS Sota triggers Insulin production-via triggering GLPproduction!! via activating NATURAL GLP1, *NOT SYNTHETIC*, like $LLY or $NVO . Did you know Sotagliflozin ($LXRX) triggers the same GLP-1 hormone as Ozempic? Here’s the exact science: Standard drugs only block SGLT2 (kidneys). Sota is a DUAL inhibitor, also blocking SGLT1 (in the gut). The Gut Mechanism: Blocking SGLT1 pushes glucose further down the intestines, naturally triggering a surge of GLP-1. 👉 For Type 2: This GLP-1 surge successfully signals the pancreas to produce insulin. 👉 For Type 1: A T1D pancreas can't make insulin. BUT, the GLP-1 surge suppresses glucagon (stops the liver from dumping sugar) and slows digestion. The Result? Massively blunted post-meal spikes, flatter curves, and a drastic reduction in the injected mealtime insulin needed. Pure SGLT2s miss this gut bonus entirely! 🧬 Read the peer-reviewed clinical data on the SGLT1/GLP-1 pathway here: https://pmc.ncbi.nlm.nih.gov/articles/PMC4831906/ #T1D
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 23 at 2:48 PM
$LXRX $VTRS $NVO = How Sotagliflozin is superior= Did you know exactly how Sotagliflozin works differently in the body? 🧬 Most people think it’s just another standard SGLT2 inhibitor that flushes sugar out through the kidneys. But it is actually a DUAL inhibitor (blocking SGLT1 & SGLT2), which changes everything for Type 1 management. Here is the biological breakdown: 1️⃣ The Kidneys (SGLT2): It blocks glucose reabsorption, flushing excess sugar out in your urine. 2️⃣ The Intestines (SGLT1): It delays glucose absorption in the gut, directly blunting post-meal blood sugar spikes. The GLP-1 Bonus: Blocking SGLT1 in the gut naturally triggers the release of GLP-1 hormones. While a T1D pancreas can't produce insulin, this GLP-1 surge suppresses glucagon (stopping the liver from dumping sugar) & slows digestion. The result? You require significantly LESS injected mealtime insulin. Dual-action means flatter curves, lower A1c, and massive insulin-sparing benefits. Education = power!
0 · Reply
Dooright
Dooright Jun. 23 at 11:35 AM
$LXRX $VTRS Love this! Doc C. 🤓
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 23 at 6:51 AM
$LXRX $VTRS
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 23 at 6:41 AM
$VTRS Share Price: $15.37 Contract Selected: Jan 15, 2027 $15 Calls Buy Zone: $1.49 – $1.84 Target Zone: $2.70 – $3.29 Potential Upside: 71% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply